Scientific Reports

Sci Rep. 7: 6197

Establishing a yeast-based screening system for discovery of human GLUT5 inhibitors and activators

Joanna Tripp¹, Christine Essl¹, Cristina V. Iancu², Eckhard Boles¹, Jun-yong Choe

junyong.choe@rosalindfranklin.edu

², Mislav Oreb

m.oreb@bio.uni-frankfurt.de

¹

1. 0000 0004 1936 9721grid.7839.5Institute of Molecular Biosciences, Goethe University, Max-von-Laue Straße 9, 60438 Frankfurt am Main, Germany

2. 0000 0004 0388 7807grid.262641.5Department of Biochemistry and Molecular Biology, Rosalind Franklin University of Medicine and Science, The Chicago Medical School, 3333 Green Bay Road, North Chicago, IL 60064 USA

© The Author(s) 2017

DOI: 10.1038/s41598-017-06262-4

Published online: 24 July 2017

Abstract

Human GLUT5 is a fructose-specific transporter in the glucose transporter family (GLUT, SLC2 gene family). Its substrate-specificity and tissue-specific expression make it a promising target for treatment of diabetes, metabolic syndrome and cancer, but few GLUT5 inhibitors are known. To identify and characterize potential GLUT5 ligands, we developed a whole-cell system based on a yeast strain deficient in fructose uptake, in which GLUT5 transport activity is associated with cell growth in fructose-based media or assayed by fructose uptake in whole cells. The former method is convenient for high-throughput screening of potential GLUT5 inhibitors and activators, while the latter enables detailed kinetic characterization of identified GLUT5 ligands. We show that functional expression of GLUT5 in yeast requires mutations at specific positions of the transporter sequence. The mutated proteins exhibit kinetic properties similar to the wild-type transporter and are inhibited by established GLUT5 inhibitors N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSNBA) and (−)-epicatechin-gallate (ECG). Thus, this system has the potential to greatly accelerate the discovery of compounds that modulate the fructose transport activity of GLUT5.

Introduction

Most glucose transporters (GLUTs), members of the SLC2 family, facilitate the passive diffusion of glucose and related monosaccharides in mammalian cells. In humans there are 14 GLUTs, which differ in tissue distribution, primary sequence, substrate specificity and affinity in accordance with physiological needs¹, ². Unlike other GLUTs capable of fructose transport, GLUT5 is fructose-specific and does not transport glucose³–⁵. GLUT5 is expressed in intestine, kidney, sperm, fat and skeletal muscle cells⁶. High-fructose diet has been implicated in type II diabetes, hypertension, hyperuricemia, obesity, nonalcoholic fatty liver disease and increased risk of cardiovascular disease⁴, ⁷–¹¹. As one of the major fructose transporters in humans, GLUT5 is an attractive therapeutic target in these diseases. For instance, in diabetic patients GLUT5 expression in muscle is significantly increased and drugs that enhance insulin action affect GLUT5 expression rate¹². A recent study showed that GLUT5-mediated fructose absorption in the small intestine is enhanced through interaction of GLUT5 with the thioredoxin-interacting protein (Txnip; a protein that regulates glucose homeostasis), and in certain forms of diabetes Txnip expression and fructose absorption increase, suggesting a mechanism that links diabetes and the metabolic syndrome¹³. Cancer cells have higher demands for carbohydrate transport than normal cells and GLUT5 is upregulated in various cancers¹⁴. In pancreatic cancer cells, fructose metabolism is preferentially channeled to nucleic acid synthesis, potentiating cancer proliferation¹⁵. Increased use of fructose mediated by GLUT5 is a metabolic feature of acute myeloid leukemia (AML) and GLUT5 inhibition reduced the malignant leukemic phenotypes of AML cells¹⁶. Importantly, GLUT5 is normally absent in breast tissue but it is expressed in breast tumors¹⁴ and breast carcinoma cell lines MCF-7 and MDA-MB-231 have high levels of GLUT5 and fructose transport¹⁷. Given the medical importance of GLUT5, its inhibitors have the potential to become drugs for treatment of cancer or diabetes, however inhibitors of GLUT5 are scarce. They include natural product compounds that inhibit GLUT1 as well, like green tea catechins¹⁸ or Rubusoside (from Rubus suavissimus)¹⁹, but also GLUT5-specific inhibitors like Astragalin-6-glucoside (a glycosylated derivative of Astragalin, from Phytolacca Americana)¹⁹ and N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSNBA)²⁰. The latter compound is the most potent and specific GLUT5 inhibitor reported so far.

Systems to assay GLUT5 transport activity include GLUT5 proteoliposomes¹⁹, ²⁰, expression of GLUT5 in Xenopus laevis oocytes²¹, and human cell lines such as MCF-7¹⁷ or Caco-2²² cells. These systems require purified protein or labor-intensive and high-cost cell cultivation. Furthermore, analysis of GLUT5 in mammalian cells needs to take into account or eliminate interference from fructose transport by other GLUT proteins. Thus, establishing a microbial system without endogenous fructose transporters would be highly desirable to simplify the assaying of GLUT5 activity.

The yeast Saccharomyces cerevisiae is not only widely used for research of fundamental processes in a eukaryotic cell, but has also proved useful for functional studies on heterologous proteins as well as for high-throughput screening approaches, many of which have medicinal relevance²³. For instance, yeast was used as a model system to study the mechanisms of neurodegenerative diseases²⁴ and cancer²⁵. For the analysis of sugar transporters from various sources, yeast has proved an excellent model system. To this end, a strain was constructed, in which all genes encoding hexose transporters and other transporters with hexose uptake activity have been deleted²⁶. The strain is designated as hexose transporter-deficient (hxt ⁰) strain, EBY.VW4000; it is not able to grow on media with glucose, fructose or mannose as the sole carbon source and grows only very slowly on galactose. For maintenance, the strain is routinely cultivated on maltose, a disaccharide that is taken up through the specialized maltose symporters encoded by the MALx1 loci²⁷. Thus, the hxt ⁰ strain offers an excellent opportunity to clone and characterize heterologous hexose transporters, e.g. from fungi²⁸ or plants²⁹ by replacing the function of endogenous transporters. However, the functional expression of mammalian glucose transporters in the hxt ⁰ background proved to be a non-trivial task. In initial trials, the human glucose transporters GLUT1 and GLUT4 did not confer growth of the hxt ⁰ strain on glucose³⁰, ³¹. In a later approach, the complementation of the hxt ⁰ phenotype by GLUT1 and GLUT4 could be achieved by prolonged incubation on glucose-containing media or UV-mutagenesis of the transformed yeast cells³². By genetic analyses, this could be attributed to mutations either in the GLUT transporter sequence or in the genome of the yeast host. For example, GLUT1 was functional only if it contained certain mutations in the second transmembrane domain or when the hxt ⁰ strain acquired the fgy1 mutation³². Once the functionality of GLUT1 and GLUT4 in yeast was established, it could be shown that they exhibit comparable properties as in the native environment concerning transport kinetics and inhibition by Cytochalasin B³². Encouraged by these successes, we aimed at establishing a functional expression of human GLUT5 in the hxt ⁰ strain in the present work.

We show that mutated versions of GLUT5 are functional in yeast, have kinetic parameters similar to those in the native environment¹⁷, and are inhibited by the GLUT5-specific inhibitor MSNBA²⁰ as well as by (−)-epicatechin-gallate (ECG), which is also a GLUT1 inhibitor¹⁸. Furthermore, inhibitor effect on GLUT5 fructose transport in the hxt ⁰ strain, as indicated by inhibitor IC₅₀ value, is similar to that determined for GLUT5 inhibition in the human breast cancer cells MCF-7 (in the case of MSNBA) and in GLUT5-expressing Xenopus laevis oocytes (in the case of ECG). Additionally, both MSNBA and ECG decrease cell growth of GLUT5-expressing hxt ⁰ strain in a dose-dependent manner. With GLUT5 expression in the hxt ⁰ strain, inhibitors or activators of GLUT5 can be determined with the radioactive fructose uptake assay or by cell growth in fructose-based media. The latter method makes this system amenable to facile and rapid high-throughput screening of GLUT5 ligands, thus accelerating GLUT5 effector discovery. Subsequent optimization of GLUT5 ligands as selective and potent in vivo chemical probes will allow for advancement of our understanding of GLUT5 biology, its role in human disease, and ultimately its pharmaceutical control.

Results

Cloning and expression of GLUT5 in the hxt⁰ strain

To generate plasmids for GLUT5 expression in yeast we used a construct previously codon-optimized for expression in insect cells and encoding a GLUT5 protein truncated for the first seven amino acids at the N-terminus (in the following referred to as GLUT5tr). The open reading frames were amplified using oligonucleotides with 30–40 basepair overhangs homologous to the MET25 promotor and CYC1 terminator of the p426MET25 vector³³. A methionine-repressible promoter was chosen to minimize the risk of possible toxic effects due to overexpression of a heterologous membrane protein. In addition to GLUT5tr ORFs, a variant, in which the codons for the initial seven amino acids were re-introduced into GLUT5tr by an oligonucleotide (the resulting construct is designated as GLUT5 in the following), was also amplified. The PCR products were co-transformed with the linearized vector into EBY.VW4000 to allow for plasmid assembly by homologous recombination (“gap-repair” procedure)³⁴. The transformants were plated on SCM-Ura medium to select for clones that have successfully assembled the plasmid. About 1000–3000 colonies were obtained on each plate. Subsequently, these clones were replica-plated onto SCF-Ura agar plates to test for the ability of GLUT5 to confer growth of yeast cells on fructose. On this medium, only a very low percentage of the clones could grow, suggesting that mutations might have occurred either in the GLUT5 sequence or in the genome of the hxt ⁰ strain, as previously observed with GLUT1 and GLUT4³². Therefore, we isolated and sequenced plasmids from the clones growing on fructose. Indeed, in GLUT5 ORFs of all isolated plasmids, single amino acid substitutions could be identified. In both GLUT5tr and GLUT5, the following mutations were isolated: S72Y (one clone of each GLUT5 and GLU5tr); S76I (three clones of each); S76N (one clone of GLUT5). Thus, in total, seven clones contained a mutation at position 76 and two at position 72. Strikingly, the positions S72 and S76 are directly adjacent to residues that align to positions W65 and V69 of GLUT1 (see alignment in the supplementary information, Supplementary Fig. S5). W65R and V69M mutations were found in GLUT1 variants, which were functional in yeast³². All these mutations are located in the second transmembrane helix (TM2) of GLUT5 or GLUT1. To test whether the mutations in the GLUT5 sequence alone are sufficient to confer growth of the hxt ⁰ strain on fructose, the plasmids were transformed into EBY.VW4000 again and growth was confirmed on fructose containing agar plates (for example, see Fig. 1a).

Figure 1View larger versionFigure 1. Functionality and subcellular distribution of GLUT5 variants. (a) Suspensions of EBY.VW4000 cells (OD600nm = 1) transformed with plasmids encoding GLUT5tr, GLUT5trS72Y, GLUT5trS76I or their fusions with sGFP were droped onto agar plates containing 2% (w/v) fructose (SCF-Ura-Met medium) or 1% (w/v) maltose (SCM-Ura medium). The latter medium was used to control the viability of the transformants and empty vector (V) was a negative control for growth on fructose. The duration of incubation at 30 °C is indicated. (b) The cells expressing the indicated variant of GLUT5-sGFP fusion proteins were cultivated in SCM-Ura-Met media until the exponential phase and analyzed by confocal laser scanning microscopy. Scale bar, 5 µm.

Subcellular localization of GLUT5 variants in yeast cells

The mutations that promoted the functionality of GLUT5 in the hxt ⁰ strain could affect the intracellular trafficking of the protein. To investigate this possibility, we created constructs for C-terminal fusion of GLUT5tr, GLUT5trS72Y and GLUT5trS76I with superfolder GFP (sGFP)³⁵. The functionality of the fusion proteins was demonstrated by growth test on fructose-containing agar plates (Fig. 1a). Subsequently, subcellular distribution of the fusion proteins was investigated by fluorescence microscopy. For all variants, an inhomogeneous distribution in the plasma membrane and a partial retention in the endomembrane systems could be observed (Fig. 1b). Thereby, we did not observe significant differences between the wild-type protein and the mutants, which indicates that the mutations do not directly affect the trafficking of the protein. Thus, some more subtle effects, such as the interactions between TM2 and lipids or the conformational flexibility of the transporter might be responsible for the functionality of the mutated protein in the yeast membrane. Similarly, the mutations in GLUT1 did not obviously affect the distribution of GLUT1 in subcellular fractions³².

Structural modeling of GLUT5 mutants

As an approach to understand the effect of S72Y and S76I mutations on the molecular level, we performed structure modeling of GLUT5 mutants. GLUT5 is a Major Facilitator Superfamily (MFS) protein. Most MFS proteins have 12 transmembrane helices (TM) organized as two domains (the N- and C-terminal domains) related by a 2-fold pseudosymmetry axis. The substrate cavity is centrally housed between the two domains. The most widely accepted transport mechanism for MFS proteins is the alternating-access model³⁶ also called “rocker-switch”, in which the substrate cavity is alternately opened to each side of membrane. Available crystal structures of MFS transporters are consistent with this model, showing the transporters in two major conformations: the so-called inward-facing (substrate cavity opened towards cytosol) and outward-facing (substrate cavity opened towards outside) conformations. Crystal structures of the mammalian GLUT5, both in the inward-facing and outward-facing conformations, were previously determined³⁷. On the basis of these crystal structures, we generated the structural models for human GLUT5 in the two conformations to examine the potential effect of S72Y and S76I mutations on GLUT5 structure. Both residues S72 and S76 are in TM2 and interact with residues from TM11 (Fig. 2), specifically F424, L428 and F432. Sequence analysis of TM2 and TM11 for the residues in positions 72, 76, 424, 428 and 432, shows variable conservation of these residues (Supplementary Material, Fig. S5). In TM2, both S72 and S76 of GLUT5 tend to be conserved or replaced in other GLUTs by small residues like Ala or Gly. Mutations of these serines to bulkier residues, Tyr in position 72 or Ile in position 76, seem to be more consequential for the inward-facing conformation in which the space between TM2 and TM11 is tight and accommodation of the mutations requires repositioning of TM2 and TM11 (Fig. 2a and c and Table 1), compared with the wild-type structure; TM2 and TM11 push away from each other to fit the bulkier substitutions in position 72 or 76. In contrast, the outward-facing conformation has sufficient space between TM2 and TM11 to adopt the substitutions without any changes in the positions of TM2 and TM11, relative to those in the wild-type structure (Fig. 2b and d). The relative movement of TM2 and TM11 in GLUT5 S72Y and S76I outward-facing conformation structures suggests that S72Y substitution is more drastic than S76I in terms of surrounding space and interactions (Table 1).

Figure 2View larger versionFigure 2. Structural models of GLUT5S72Y and GLUT5S76I mutants. Outward-facing (a) and inward-facing (b) structures of mutants. S72 and S76 are located toward the lumen in TM helix 2. Close-up showing the location of Y72 and I76 in the outward-facing (c) and inward-facing (d) conformations of the transporter. Y72 and I76 interact with hydrophobic residues from TM helix 11. Figure was generated with Molscript⁴⁷ and Raster3D⁴⁸.

See full tableTable 1. Movement of Cα atoms of TM helices 2 and 11 in GLUT5S72Y or GLUT5S76I relative to those in the wild-type, for the inward-facing conformation structures.

Functional studies on GLUT5 mutants

Since GLUT5 conferred a rather slow growth on synthetic media (about five days until colonies appeared on agar plates; see Fig. 1a), we generated plasmids with dominant markers that can be maintained on rich media (YEP) for further functional studies. The ORFs of GLUT5tr, GLUT5trS72Y and GLUT5trS76I were placed under the control of the (constitutive) truncated HXT7 promoter in the multicopy vector pRS72K. The growth of EBY.VW4000 transformed with these plasmids was first assessed on solid media (Supplementary Fig. S6). A plasmid encoding the endogenous hexose transporter Hxt7 capable of fructose transport³⁸ and the empty vector were used as positive and negative controls, respectively. In line with the results obtained on synthetic media, only the mutated GLUT5 variants, but not the wild-type, could support growth on fructose. Next, we analyzed the growth of the transformants in liquid media using a Cell Growth Quantifier (Aquila Biolabs)³⁹. Both GLUT5tr mutants showed significant growth in liquid media, albeit with a longer lag phase and slower rate compared to the transformants expressing the endogenous high-affinity hexose transporter HXT7 (Fig. 3a).

Figure 3View larger versionFigure 3. Growth analysis of GLUT5-transformed hxt ⁰ cells. (a) The EBY.VW4000 cells transformed with plasmids encoding GLUT5trS72Y, GLUT5trS76I or Hxt7 were cultivated in YEP media containing 1% (w/v) fructose and 200 µg/ml of G418 for plasmid selection. The cells transformed with the empty vector were used as a negative control. The growth was measured using the Cell Growth Quantifier (Aquila Biolabs). (b–d) Indicated amount of MSNBA was added to the cultures and the growth was measured as in (a). The same color code is used throughout panels b–d.

Further, we investigated whether the mutations have altered the properties of GLUT5 concerning transport kinetics and action of inhibitors. Recently, MSNBA was identified as a potent and specific inhibitor of GLUT5²⁰. To test the inhibition of yeast-expressed GLUT5, variable concentrations (1–50 µm) of MSNBA were added to YEPF media and the growth of the transformants was monitored. As expected, the growth of the cells expressing GLUT5trS72Y and GLUT5trS76I was delayed by MSNBA in a concentration dependent manner, while there was virtually no influence on cells expressing HXT7 (compare Fig. 3b–d). This observation confirms a GLUT5-specific inhibition mechanism. To further corroborate that mutated GLUT5 in yeast behaves like the WT protein in animal cells, we performed a similar assay with ECG, an inhibitor that is structurally not related to MSNBA. Again, the growth of the hxt ⁰ cells expressing GLUT5 variants was delayed by the inhibitor, while the HXT7 expressing control was not affected (Supplementary Fig. S7). For a quantitative insight into transport kinetics of GLUT5 mutants, we determined the Michaelis-constant (KM values) for fructose (Fig. 4a,b and Table 2) and half maximal inhibitory concentration (IC₅₀ values) of MSNBA and ECG (Fig. 4c,d and Table 2). Although there is a slight variation between the mutants, their kinetic parameters are similar to those determined in MCF-7 cells¹⁷, ²⁰ or X. laevis oocytes¹⁸, indicating that the mutations do not have a major influence on the transport mechanism. Reported KM values for human GLUT5 fructose uptake vary between 6 and 15 mM³, ¹⁷, ⁴⁰.

Figure 4View larger versionFigure 4. Transport kinetics and inhibition of GLUT5 mutants in hxt ⁰ cells. The initial uptake velocity vt (expressed as nmol fructose transported per minute per mg cell dry weight) was measured for GLUT5trS72Y (a) and GLUT5trS76I (b) and plotted against sugar concentration. Mean values and standard deviation were calculated from biological triplicates. The lines represent a least-square fit to the Michaelis-Menten equation. The uptake of fructose was measured at variable MSNBA (c) and ECG (d) concentrations and the uptake velocity was normalized to that in the absence of the inhibitor. The IC₅₀ values were calculated by nonlinear algorithm plots supplied by Prism (GraphPad Software).

See full tableTable 2. GLUT5 transport kinetics and inhibition in hxt ⁰ yeast cells (see also Fig. 4).

Discussion

In this work, we successfully complemented the hexose transporter-deficient strain EBY.VW4000 with the human fructose transporter GLUT5. The wild-type protein was not active in the hxt ⁰ strain or even in its derivative EBY.S7 carrying the fgy1 mutation that promoted the activity of GLUT1³². However, several clones that carried random, PCR-born mutations in the GLUT5 ORF could be identified, which were capable of fructose transport. Interestingly, in all clones serine residues (at positions 72 and 76) were mutated. They are located in the same region of the protein as mutations previously found to be required for GLUT1 activity in hxt ⁰ strains (Supplementary Fig. S5). The mutations appeared to have no influence on the subcellular distribution of the protein (Fig. 1b), similar to what was observed with GLUT1 previously³². Thus, it is possible that the mutations affect the conformational dynamics of the transporter in the non-native lipid environment. For instance, GLUT3 and GLUT4 transport activities depend on the type of lipids used for proteoliposome generation, with anionic phospholipids playing a significant role in stabilizing the transporters and conical lipids enhancing transport activity⁴¹. Strikingly, the mutation fgy4, that is required for GLUT4 functionality in the hxt ⁰ strain³², prevents the last step of ergosterol biosynthesis (i.e. the mutants accumulate ergosta-5,7,22,24(28)-tetraen-3β-ol in the plasma membrane; E. Boles, unpublished result). This further underscores the impact of protein-lipid interactions.

Interestingly, both mutations in TM2 (S72Y and S76I) seem to favor the outward-facing conformation; the residue substitutions require TM2 and 11 to move apart by 1–2 Å in the inward-facing conformation models (Table 1 and Fig. 2). Analysis of GLUT sequences shows that positions 72 and 76 are generally occupied by small side-chains. The substitutions of S76 with a branched hydrophobic residue or of S72 with a bulky Tyrosine, impacts the inward-facing conformation in which there is close juxtaposition of TM2 and TM11. Thus, we speculate that the mutations in TM2 destabilize the inward-facing conformation relative to the outward-facing conformation of GLUT5. It is possible that favoring the outward-facing conformation of the transporter compensates for alterations in the conformational dynamics of the transporter in the non-native lipid milieu and this confers an advantage to these GLUT5 mutants over the wild-type with respect to fructose transport by reducing the overall length of the catalytic cycle. Regardless of the mechanism underlying the effect of the mutations, it is important for screening approaches that they do not have a major influence on transport kinetics and inhibition. Indeed we show here that the KM of fructose uptake by GLUT5 mutants in yeast hxt ⁰ cells (abbreviated hxt ⁰ GLUT5; Table 2) is comparable with that determined in other systems used to assay GLUT5)³, ¹⁷, ⁴⁰. Additionally, the effects of reported GLUT5 inhibitors on fructose uptake in the hxt ⁰ GLUT5 were similar to previous results in other GLUT5 systems including human cancer cell line (MCF-7) and GLUT5 expressed in X. laevis oocytes. Thus, with the hxt ⁰ GLUT5 system IC₅₀ value for fructose uptake inhibition by (−)-epicatechin-gallate (ECG) was comparable to the Ki value previously reported¹⁸. Also the IC₅₀ for MSNBA inhibition of fructose uptake by hxt ⁰ GLUT5 is comparable to that determined in human breast carcinoma MCF-7 cells and ~10-fold lower than that determined in GLUT5 proteoliposomes²⁰, making the yeast system superior to GLUT5 proteoliposomes and comparable to human cell lines systems in assessing GLUT5 inhibition.

Importantly, inhibition of GLUT5 transport by ECG and MSNBA evidenced in cell-growth supports the use of hxt ⁰ GLUT5 system for facile, low-cost and high-throughput screening of GLUT5 inhibitors. High-throughput screening of GLUT5 ligands by hxt ⁰ yeast cell-growth is currently being implemented in our laboratories. Furthermore, hxt ⁰ GLUT5 system does not need to account for complicating contributions to the fructose transport from other GLUTs or carbohydrate transporters, as is the case in animal cell lines. Compared to alternative yeast strains, e.g. RE700A, which lacks only the major hexose transporters HXT1-HXT7³⁸ and which was successfully used to express and characterize human GLUT1⁴², the hxt ⁰ strain EBY.VW4000 offers the advantage that no residual hexose transporters are left in its genome. Many of the remaining hexose transporters in RE700A, e.g. Hxt11 or Gal2 are repressed on glucose, but can be upregulated under selective pressure²⁶, which could likely lead to a high frequency of suppressor mutations and therefore severely complicate high-throughput screening approaches. Thus, despite the fact that several genomic alterations have occurred in the hxt ⁰ strain due to the repeated use of the loxP-Cre recombinase system⁴³, it has remained the most popular and widely used system for characterization of heterologous hexose transporters. While GLUT5 proteoliposome system is also hexose transporter-free, it is more labor-intensive than hxt ⁰ GLUT5. Overall, hxt ⁰ GLUT5 is a convenient, versatile, low-cost, GLUT5-specific, and fast system for identification and characterization of human GLUT5 ligands, allowing the screening of compound libraries for potential GLUT5 effectors that could serve as drugs for cancer, metabolic disease, and diabetes. Using a growth-based, microbial screening system will dramatically accelerate the cycle of inhibitor discovery and characterization.

Methods

Yeast strains, media and growth conditions

Construction of the strain EBY.VW4000 was described previously²⁶ and the relevant genotype is shown in Supplementary Table S1. Plasmid-free cells were grown in standard YEP-media (1%(w/v) yeast extract, 2%(w/v) peptone) supplemented with 1% (w/v) maltose for maintenance and preparation of competent cells. Frozen competent cells were prepared and transformed according to the established protocol⁴⁴. The synthetic complete (SC) medium³⁹ was supplemented with the appropriate carbon source (as indicated in the figure legends), whereby Uracil was dropped out (-Ura) for plasmid selection and Methionine was omitted to induce the expression from the MET25 promoter, where indicated. For selection of plasmids containing the kanMX4 cassette, 200 µg/ml G-418 was added to the YEP-based media.

PCR and plasmid construction

Codon optimized GLUT5 was synthesized by GenScript. The sequences are listed in Supplementary Table S3. The primers used for ORF amplification are listed in Supplementary Table S2. The PCR reactions (50 µl final volume) contained 10 ng of template DNA, 500 nM of each primer, 0.2 mM of deoxy-nucleotides, and 1 Unit of the Phusion polymerase in 1x concentration of the supplied HF-buffer (Thermo Fisher). After initial denaturation (2 min at 98 °C), 28 cycles were performed (15 s at 98 °C; 30 s at 58 °C; 45 s at 72 °C). The PCR products (500 ng) were co-transformed with 800 ng of BamHI/XhoI linearized p426MET25 vector into frozen competent cells of EBY.VW4000 to allow for plasmid assembly by homologous recombination (gap-repair procedure)³⁴. The transformants were plated on SC-Ura media with 1% (w/v) maltose (SCM-Ura). After two days of incubation at 30 °C, the colonies were replica-plated onto SC-Ura media containing 2% (w/v) fructose (SCF-Ura). The resulting colonies were subcultivated and the plasmid DNA was isolated by the standard alkaline lysis protocol and transferred into E. coli DH10B cells by electroporation. The plasmid DNA was isolated from E. coli overnight cultures using a commercial kit according to manufacturer’s recommendations and sequenced at GATC Biotech (Konstanz, Germany). After the mutations in the GLUT5 sequence were isolated, the ORFs from the p426MET25-based plasmids were amplified as described above and inserted into the pRS72K vector between the truncated HXT7 promoter and CYC1 terminator by the gap-repair procedure. sGFP was inserted by the gap-repair method into p426MET25-based GLUT5 constructs, which were linearized with XhoI between the GLUT5 ORF and the CYC1 terminator. The relevant plasmid properties are listed in Supplementary Table S4.

Growth tests on solid and liquid media

For growth tests on agar plates, cells were pre-grown on selective maltose-containing medium and washed two times with sterile water. The cell density was adjusted to OD600nm = 1. Five microliters of the cell suspension were then spotted onto appropriate agar plates, which were incubated at 30 °C for time periods indicated in the figure legends.

The growth kinetics in liquid cultures was measured with the Cell Growth Quantifier (CGQ; Aquila Biolabs). Precultures were grown overnight in YEP containing 1% (w/v) maltose and 200 µg/ml G-418 for plasmid selection. The cells were washed twice with sterile water and resuspended to a final OD600nm = 0.5 in YEP medium containing 1% (w/v) fructose and 200 µg/ml G-418. The cultures were filled into 300 ml shake flasks and mounted onto the CGQ sensor plate. The measurement was performed as previously described³⁹.

Fluorescence microscopy

For the in vivo investigation of protein localization, EBY.VW4000 cells expressing the indicated constructs were grown in selective SCM-Ura media without Methionine until an OD600nm = 2.0–2.5 was reached. Cells were harvested by centrifugation at 3,000 × g for 1 min and resuspended in the same media containing 0.3% (w/v) low melting agarose for immobilization. Ten microliters were applied to an object plate, sealed with a cover slip, and analyzed with a Confocal Laser Scanning Microscope (TCS SP5 378, Leica Microsystems AG, Wetzlar, Germany) for GFP fluorescence.

Sugar uptake and inhibition assays

GLUT5 (GLUT5trS72Y or GLUT5trS76I) expressing EBY.VW4000 yeast strains were grown in 10 ml of YEPM media with 100 µg/L antibiotic G-418, at 29 °C, in an incubator with shaking (220 rpm) for one day. Two mililiters of cell culture were centrifuged at 10,000 g for 30 seconds and the pellet was resuspended in 50 ml of YEPF media with 100 µg/L G-418. The cells were grown as above to OD600nm ~ 10 (for 1–2 days), then harvested by centrifugation at 5,000 g for 2 minutes. The cell pellet was resuspended in 50 ml PBS buffer and centrifuged once more. The pellet was resuspended in PBS buffer at OD600nm~1.5. Cells that did not express GLUT5 were used as background control. Transport assay was initiated at 22 °C by the addition of 2 μl of ¹⁴C-radiolabeled fructose (50 nCi, 0.2 nmol) and various concentrations of cold-fructose to 100 or 200 μl yeast cell solution with/without the inhibitor N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSNBA, Enamine) or (−)-epicatechin-gallate (ECG, Cayman). The transport was stopped after 20 minutes with ice-chilled quench buffer (0.1 M KPi, pH 5.5, 0.1 M LiCl), the solution was filtered with 0.4 µm cellulose nitrate membrane filter (Whatman), and the filter was washed twice with the quench buffer. The membrane filter was placed into a vial filled with BioSafe II scintillation liquid (Research Products International Corp.) and radioactivity was measured with Becker LS 6500 Multi-purpose Scintillation Counter. Kinetic parameters were determined by non-linear algorithm plots supplied by Prism (GraphPad Software).

Modeling of GLUT5S76I and GLUT5S72Y structures

GLUT5 model structures of inward- and outward-facing conformations were generated with COOT⁴⁵ on the basis of crystal structure of bovine GLUT5 (PDB ID 4YB9) for the inward-facing conformation and mouse GLUT5 (PDB ID 4YBQ) for the outward-facing conformation³⁷. Energy minimization of mutant structures was performed with Phenix⁴⁶.

Supplementary Material

Open In Web Browser

Footnotes

Electronic supplementary material

Supplementary information accompanies this paper at doi:10.1038/s41598-017-06262-4

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

This work was supported financially by the government of the State of Hesse, Federal Republic of Germany (to E.B. and M.O.), by NIH Grants R01-DK091754 (to J.C.) and R01-GM123103 (to M.O. and J.C.).

Author Contributions

J.C. and M.O. planned and guided the project. C.E., C.I. and J.T. performed the experiments. E.B. provided advice and resources. C.I., J.C., J.T. and M.O. analyzed data and wrote the manuscript. All authors read and approved the manuscript.

Notes

Competing Interests

The authors declare that they have no competing interests.

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

PMC Copyright Notice

The articles available from the PMC site are protected by copyright, even though access is free. Copyright is held by the respective authors or publishers who provide these articles to PMC. Users of PMC are responsible for complying with the terms and conditions defined by the copyright holder.

Users should assume that standard copyright protection applies to articles in PMC, unless an article contains an explicit license statement that gives a user additional reuse or redistribution rights. PMC does not allow automated/bulk downloading of articles that have standard copyright protection.

See the copyright notice on the PMC site, https://www.ncbi.nlm.nih.gov/pmc/about/copyright/, for further details and specific exceptions.

References

Barron CC, Bilan PJ, Tsakiridis T, Tsiani E, authors. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016;65:124–139. [Cross Ref] [PubMed]

Mueckler M, Thorens B, authors. The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 2013;34:121–138. [Cross Ref] [PubMed]

Burant CF, Takeda J, Brot-Laroche E, Bell GI, Davidson NO, authors. Fructose transporter in human spermatozoa and small intestine is GLUT5. J. Biol. Chem. 1992;267:14523–14526. [PubMed]

Thorens B, Mueckler M, authors. Glucose transporters in the 21st Century. Am. J. Physiol. Endocrionol. Metab. 2010;298:E141–145. [Cross Ref]

Uldry M, Thorens B, authors. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 2004;447:480–489. [Cross Ref] [PubMed]

Douard V, Ferraris RP, authors. Regulation of the fructose transporter GLUT5 in health and disease. Am. J. Physiol. Endocrionol. Metab. 2008;295:E227–37. [Cross Ref]

Bray GA, author. Fructose and risk of cardiometabolic disease. Curr. Atheroscler. Rep. 2012;14:570–578. [Cross Ref] [PubMed]

Tappy L, Le K-A, authors. Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 2010;90:23–46. [Cross Ref] [PubMed]

Bray GA, Nielsen SJ, Popkin BM, authors. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am. J. Clin. Nutr. 2004;79:537–543. [PubMed]

Johnson RJ, et al., authors. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am. J. Clin. Nutr. 2007;86:899–906. [PubMed]

Johnson RJ, et al., authors. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307–3315. [Cross Ref] [PubMed]

Stuart CA, Howell MEA, Yin D, authors. Overexpression of GLUT5 in diabetic muscle is reversed by pioglitazone. Diabetes Care. 2007;30:925–931. [Cross Ref] [PubMed]

Dotimas JR, et al., authors. Diabetes regulates fructose absorption through thioredoxin-interacting protein. eLife. 2016;5:e18313 [Cross Ref] [PubMed]

Godoy A, et al., authors. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J. Cell. Physiol. 2006;207:614–627. [Cross Ref] [PubMed]

Liu H, et al., authors. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res. 2010;70:6368–6376. [Cross Ref] [PubMed]

Chen W-L, et al., authors. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. Cancer Cell. 2016;30:779–791. [Cross Ref] [PubMed]

Zamora-Leon SP, et al., authors. Expression of the fructose transporter GLUT5 in human breast cancer. Proc. Natl. Acad. Sci. USA. 1996;93:1847–1852. [Cross Ref] [PubMed]

Slavic K, Derbyshire ET, Naftalin RJ, Krishna S, Staines HM, authors. Comparison of effects of green tea catechins on apicomplexan hexose transporters and mammalian orthologues. Mol. Biochem. Parasitol. 2009;168:113–116. [Cross Ref] [PubMed]

George Thompson AM, Iancu CV, Nguyen TTH, Kim D, Choe J-y, authors. Inhibition of human GLUT1 and GLUT5 by plant carbohydrate products; insights into transport specificity. Sci. Rep. 2015;5:12804 [Cross Ref] [PubMed]

George Thompson AM, et al., authors. Discovery of a specific inhibitor of human GLUT5 by virtual screening and in vitro transport evaluation. Sci. Rep. 2016;6:24240 [Cross Ref] [PubMed]

Kayano T, et al., authors. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). J. Biol. Chem. 1990;265:13276–13282. [PubMed]

Lee Y, Lim Y, Kwon O, authors. Selected phytochemicals and culinary plant extracts inhibit fructose uptake in Caco-2 cells. Molecules. 2015;20:17393–17404. [Cross Ref] [PubMed]

Mager WH, Winderickx J, authors. Yeast as a model for medical and medicinal research. Trends Pharmacol. Sci. 2005;26:265–273. [Cross Ref] [PubMed]

Fruhmann, G. et al. Yeast buddies helping to unravel the complexity of neurodegenerative disorders. Mech. Ageing Dev. pii: S0047-6374(16)30057-4 (2016).

Guaragnella N, et al., authors. The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2. FEMS Yeast Res. 2014;14:2–16. [Cross Ref] [PubMed]

Wieczorke R, et al., authors. Concurrent knock-out of at least 20 transporter genes is required to block uptake of hexoses in Saccharomyces cerevisiae. FEBS Lett. 1999;464:123–128. [Cross Ref] [PubMed]

Chow THC, Sollitti P, Marmur J, authors. Structure of the multigene family of MAL loci in Saccharomyces. Mol. Gen. Genet. 1989;217:60–69. [Cross Ref] [PubMed]

Schussler A, Martin H, Cohen D, Fitz M, Wipf D, authors. Characterization of a carbohydrate transporter from symbiotic glomeromycotan fungi. Nature. 2006;444:933–936. [Cross Ref] [PubMed]

Chen L-Q, et al., authors. Sugar transporters for intercellular exchange and nutrition of pathogens. Nature. 2010;468:527–532. [Cross Ref] [PubMed]

Kasahara T, Kasahara M, authors. Expression of the rat GLUT1 glucose transporter in the yeast Saccharomyces cerevisiae. Biochem. J. 1996;315:177–182. [Cross Ref] [PubMed]

Kasahara T, Kasahara M, authors. Characterization of rat Glut4 glucose transporter expressed in the yeast Saccharomyces cerevisiae: comparison with Glut1 glucose transporter. Biochim. Biophys. Acta. 1997;1324:111–119. [Cross Ref] [PubMed]

Wieczorke R, Dlugai S, Krampe S, Boles E, authors. Characterisation of mammalian GLUT glucose transporters in a heterologous yeast expression system. Cell Physiol. Biochem. 2003;13:123–134. [Cross Ref] [PubMed]

Mumberg D, Müller R, Funk M, authors. Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression. Nucleic Acids Res. 1994;22:5767–5768. [Cross Ref] [PubMed]

Oldenburg KR, Vo KT, Michaelis S, Paddon C, authors. Recombination-mediated PCR-directed plasmid construction in vivo in yeast. Nucleic Acids Res. 1997;25:451–452. [Cross Ref] [PubMed]

Pedelacq J-D, Cabantous S, Tran T, Terwilliger TC, Waldo GS, authors. Engineering and characterization of a superfolder green fluorescent protein. Nat. Biotechnol. 2006;24:79–88. [Cross Ref] [PubMed]

Jardetzky O, author. Simple allosteric model for membrane pumps. Nature. 1966;211:969–970. [Cross Ref] [PubMed]

Nomura N, et al., authors. Structure and mechanism of the mammalian fructose transporter GLUT5. Nature. 2015;526:397–401. [Cross Ref] [PubMed]

Reifenberger E, Freidel K, Ciriacy M, authors. Identification of novel HXT genes in Saccharomyces cerevisiae reveals the impact of individual hexose transporters on glycolytic flux. Mol. Microbiol. 1995;16:157–167. [Cross Ref] [PubMed]

Bruder S, Reifenrath M, Thomik T, Boles E, Herzog K, authors. Parallelised online biomass monitoring in shake flasks enables efficient strain and carbon source dependent growth characterisation of Saccharomyces cerevisiae. Microb. Cell Fact. 2016;15:127 [Cross Ref] [PubMed]

Kane S, Seatter MJ, Gould GW, authors. Functional studies of human GLUT5: effect of pH on substrate selection and an analysis of substrate interactions. Biochem. Biophys. Res. Comm. 1997;238:503–505. [Cross Ref] [PubMed]

Hresko RC, Kraft TE, Quigley A, Carpenter EP, Hruz PW, authors. Mammalian glucose transporter activity is dependent upon anionic and conical phospholipids. J. Biol. Chem. 2016;291:17271–17282. [Cross Ref] [PubMed]

Levine KB, Robichaud TK, Hamill S, Sultzman LA, Carruthers A, authors. Properties of the human erythrocyte glucose transport protein are determined by cellular context. Biochemistry. 2005;44:5606–5616. [Cross Ref] [PubMed]

Solis-Escalante, D. et al. The genome sequence of the popular hexose-transport-deficient Saccharomyces cerevisiae strain EBY.VW4000 reveals LoxP/Cre-induced translocations and gene loss. FEMS Yeast Res. 15, doi:10.1093/femsyr/fou004 (2015).

Gietz RD, Schiestl RH, authors. Frozen competent yeast cells that can be transformed with high efficiency using the LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2007;2:1–4. [Cross Ref] [PubMed]

Emsley P, Lohkamp B, Scott WG, Cowtan K, authors. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010;66:486–501. [Cross Ref] [PubMed]

Adams PD, et al., authors. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010;66:213–221. [Cross Ref] [PubMed]

Esnouf RM, author. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr. D Biol. Crystallogr. 1999;55:938–940. [Cross Ref] [PubMed]

Merritt EA, Murphy ME, authors. Raster3D Version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 1994;50:869–873. [Cross Ref] [PubMed]

[Back]

Figure 1.

Functionality and subcellular distribution of GLUT5 variants. (a) Suspensions of EBY.VW4000 cells (OD600nm = 1) transformed with plasmids encoding GLUT5tr, GLUT5trS72Y, GLUT5trS76I or their fusions with sGFP were droped onto agar plates containing 2% (w/v) fructose (SCF-Ura-Met medium) or 1% (w/v) maltose (SCM-Ura medium). The latter medium was used to control the viability of the transformants and empty vector (V) was a negative control for growth on fructose. The duration of incubation at 30 °C is indicated. (b) The cells expressing the indicated variant of GLUT5-sGFP fusion proteins were cultivated in SCM-Ura-Met media until the exponential phase and analyzed by confocal laser scanning microscopy. Scale bar, 5 µm.

[Back]

[Back]

Figure 2.

Structural models of GLUT5S72Y and GLUT5S76I mutants. Outward-facing (a) and inward-facing (b) structures of mutants. S72 and S76 are located toward the lumen in TM helix 2. Close-up showing the location of Y72 and I76 in the outward-facing (c) and inward-facing (d) conformations of the transporter. Y72 and I76 interact with hydrophobic residues from TM helix 11. Figure was generated with Molscript⁴⁷ and Raster3D⁴⁸.

[Back]

[Back]

Table 1.

Movement of Cα atoms of TM helices 2 and 11 in GLUT5S72Y or GLUT5S76I relative to those in the wild-type, for the inward-facing conformation structures.

Residue position in TM2 | S72Y (Å) | S76I (Å) | Residue position in TM11 | S72Y (Å) | S76I (Å)
78 | 0.5 | 0.2 | 423 | −0.2 | −0.4
79 | 0.2 | 0.2 | 424 | −0.2 | −0.9
78 | 0.5 | 0.2 | 425 | −0.3 | −0.9
77 | 0.7 | 0.4 | 426 | −0.3 | −0.4
76 | 0.8 | 0.4 | 427 | −0.3 | −0.7
75 | 0.4 | 0.2 | 428 | −0.4 | −1.3
74 | 1.8 | 0.2 | 429 | −0.5 | −1.2
73 | 1.7 | 0.5 | 430 | −0.5 | −0.5
72 | 1.6 | 0.7 | 431 | −0.9 | −0.6
71 | 0.4 | 0.6 | 432 | −0.7 | −0.6
70 | 0.9 | 0.5 | 433 | −0.7 | −0.5
69 | 1.4 | 0.6 | 434 | −0.8 | −0.2
68 | 1.0 | 0.7 | 435 | −0.9 | −0.2
67 | 0.5 | 0.4 | 436 | −0.9 | −0.2

Average movements for 12 residues around the mutated residues (highlighted in italics for S72Y and bold for S76I) are 2.0 Å (for S72Y) or 1.1 Å (for S76I).

[Back]

[Back]

Figure 3.

Growth analysis of GLUT5-transformed hxt ⁰ cells. (a) The EBY.VW4000 cells transformed with plasmids encoding GLUT5trS72Y, GLUT5trS76I or Hxt7 were cultivated in YEP media containing 1% (w/v) fructose and 200 µg/ml of G418 for plasmid selection. The cells transformed with the empty vector were used as a negative control. The growth was measured using the Cell Growth Quantifier (Aquila Biolabs). (b–d) Indicated amount of MSNBA was added to the cultures and the growth was measured as in (a). The same color code is used throughout panels b–d.

[Back]

[Back]

Figure 4.

Transport kinetics and inhibition of GLUT5 mutants in hxt ⁰ cells. The initial uptake velocity vt (expressed as nmol fructose transported per minute per mg cell dry weight) was measured for GLUT5trS72Y (a) and GLUT5trS76I (b) and plotted against sugar concentration. Mean values and standard deviation were calculated from biological triplicates. The lines represent a least-square fit to the Michaelis-Menten equation. The uptake of fructose was measured at variable MSNBA (c) and ECG (d) concentrations and the uptake velocity was normalized to that in the absence of the inhibitor. The IC₅₀ values were calculated by nonlinear algorithm plots supplied by Prism (GraphPad Software).

[Back]

[Back]

Table 2.

GLUT5 transport kinetics and inhibition in hxt ⁰ yeast cells (see also Fig. 4).

GLUT5 variant | KM [mM] | IC₅₀ of MSNBA [µM] | IC₅₀ of ECG [µM]
S72Y | 10.8 ± 1.0 | 26.6 ± 6.7 | 180 ± 11
S76I | 14.6 ± 1.1 | 6.3 ± 0.7 | 140 ± 11
WT in MCF-7 cells or in X. laevis oocytes* | ~10¹⁷* | 5.8 ± 0.5²⁰* | Ki = 117 ± 54¹⁸*

*Values from References indicated in superscript.

[Back]